XSHE
300529
Market cap1.79bUSD
Oct 09, Last price
15.12CNY
1D
0.80%
1Q
-5.79%
Jan 2017
-67.87%
IPO
-11.63%
Name
Jafron Biomedical Co Ltd
Chart & performance
P/E
22.66
P/S
6.00
EPS
0.67
Div yield, %
5.33%
Shrs. gr., 5y
-0.96%
Rev. gr., 5y
0.62%
Revenues
2.01b
-24.86%
Net income
533m
-35.04%
CFO
721m
-31.38%
Dividend
Jun 01, 20260.52 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jafron Biomedical Co.,Ltd. engages in the research and development, production, and sale of blood purification products for hemadsorption field worldwide. The company offers therapies for kidney, liver, and critical diseases, as well as poisoning. It also provides HA series disposable hemoperfusion cartridge; BS series disposable plasma bilirubin perfusion adsorption column; blood purification machine; and other products, such as JM hemodialyzer, DNA230, disinfectant, hemodialysis concentrate, resin bandage, online hemodialysis B powder bag/bucket, PGA absorbable suture with needle, syringe and infusion pumps. The company was founded in 1989 and is based in Zhuhai, China.
Key people
Xueyun Liao
Chief Financial Officer, Director · since 2023
Fan Dong
Chairman of the Board, General Manager · since 2022
Feng Li
Deputy General Manager, Director, Assistant to General Manager · since 2024
Xianmin Tang
Deputy General Manager, Director · since 2010
Rui Wang
Deputy General Manager · since 2023
Aijun Wu
Deputy General Manager, Chief Strategy Officer · since 2020
Qingwu Xie
Assistant to President, Director · since 2023
Cong Huang
Secretary of the Board · since 2022
Wen Lei
Director · since 2020
Guoqing Guo
Independent Director · since 2023
Zhihao Wen
Independent Director · since 2023
Yanjun Xu
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||